Core Viewpoint - XuanZhu Biotech-B (02575) has seen a stock increase of over 5%, currently trading at 62.65 HKD with a transaction volume of 23.56 million HKD, following the announcement of positive interim results from the BRIGHT-3 clinical trial for its drug, Pyrotinib, in treating HR+/HER2- advanced breast cancer [1][1][1] Group 1 - XuanZhu Biotech presented interim analysis results of the Phase III BRIGHT-3 trial at the 2025 European Society for Medical Oncology (ESMO), showcasing the efficacy of Pyrotinib in combination with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer [1][1][1] - The China National Medical Products Administration officially accepted the new drug application for Pyrotinib combined with aromatase inhibitors (AI) for HR+/HER2- advanced breast cancer on May 14, 2025, based on the interim data from the BRIGHT-3 study [1][1][1] Group 2 - Pyrotinib is a novel CDK2/4/6 inhibitor with a multi-target synergistic mechanism that effectively suppresses tumor cell proliferation and significantly reduces common hematological toxicities associated with traditional CDK4/6 inhibitors [1][1][1] - In May 2023, Pyrotinib was approved in China for use in adult patients with HR+/HER2- advanced or metastatic breast cancer, either in combination with fulvestrant for patients with disease progression after prior endocrine therapy or as a monotherapy for patients who have experienced disease progression after two or more endocrine therapies and one chemotherapy [1][1][1]
港股异动 | 轩竹生物-B(02575)再涨超5% 公司在ESMO年会展示吡洛西利治疗乳腺癌临床III期研究数据